bluebird bio analyst ratings
bluebird bio analyst ratings
藍鳥生物分析師評級
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/05/2022 | -11.51% | Barclays | $3 → $5 | Upgrades | Underweight → Equal-Weight |
| 08/02/2022 | 41.59% | Raymond James | → $8 | Upgrades | Market Perform → Outperform |
| 05/24/2022 | -64.6% | Goldman Sachs | $3 → $2 | Maintains | Sell |
| 05/17/2022 | -46.9% | Morgan Stanley | $5 → $3 | Maintains | Underweight |
| 05/10/2022 | -46.9% | Barclays | $4 → $3 | Maintains | Underweight |
| 04/06/2022 | — | Cowen & Co. | Downgrades | Outperform → Market Perform | |
| 04/06/2022 | 41.59% | SVB Leerink | $10 → $8 | Maintains | Market Perform |
| 03/08/2022 | 41.59% | Wells Fargo | $12 → $8 | Maintains | Equal-Weight |
| 03/07/2022 | -11.51% | Morgan Stanley | $6 → $5 | Maintains | Underweight |
| 03/07/2022 | -29.21% | Barclays | $13 → $4 | Downgrades | Equal-Weight → Underweight |
| 03/07/2022 | 76.98% | SVB Leerink | $11 → $10 | Maintains | Market Perform |
| 01/06/2022 | 76.98% | Morgan Stanley | $11 → $10 | Maintains | Underweight |
| 11/08/2021 | 76.98% | Goldman Sachs | $23 → $10 | Downgrades | Neutral → Sell |
| 11/08/2021 | 130.08% | Barclays | $20 → $13 | Maintains | Equal-Weight |
| 11/08/2021 | 94.68% | Morgan Stanley | → $11 | Downgrades | Equal-Weight → Underweight |
| 09/22/2021 | 307.07% | Mizuho | $29 → $23 | Maintains | Buy |
| 08/10/2021 | 253.97% | Canaccord Genuity | $86 → $20 | Downgrades | Buy → Hold |
| 08/10/2021 | 307.07% | Goldman Sachs | $63 → $23 | Downgrades | Buy → Neutral |
| 08/10/2021 | 342.46% | Wells Fargo | $60 → $25 | Downgrades | Overweight → Equal-Weight |
| 07/16/2021 | 519.45% | Morgan Stanley | $36 → $35 | Maintains | Equal-Weight |
| 07/01/2021 | 519.45% | Berenberg | → $35 | Downgrades | Buy → Hold |
| 04/19/2021 | 537.15% | Morgan Stanley | $45 → $36 | Maintains | Equal-Weight |
| 03/29/2021 | 1174.29% | SVB Leerink | $69 → $72 | Maintains | Outperform |
| 03/10/2021 | 1121.2% | Mizuho | $34 → $69 | Upgrades | Neutral → Buy |
| 03/02/2021 | 696.43% | Morgan Stanley | $50 → $45 | Maintains | Equal-Weight |
| 02/17/2021 | 590.24% | JP Morgan | $76 → $39 | Downgrades | Overweight → Neutral |
| 11/11/2020 | 1032.7% | Berenberg | → $64 | Initiates Coverage On | → Buy |
| 11/11/2020 | 784.92% | Morgan Stanley | $68 → $50 | Maintains | Equal-Weight |
| 11/05/2020 | 873.42% | Piper Sandler | $70 → $55 | Maintains | Neutral |
| 11/05/2020 | 1333.58% | B of A Securities | $100 → $81 | Maintains | Buy |
| 11/05/2020 | 1652.15% | SVB Leerink | $133 → $99 | Maintains | Outperform |
| 11/05/2020 | 891.12% | BMO Capital | → $56 | Downgrades | Outperform → Market Perform |
| 10/20/2020 | 2076.91% | Mizuho | → $123 | Initiates Coverage On | → Buy |
| 08/10/2020 | 1103.5% | Morgan Stanley | $73 → $68 | Maintains | Equal-Weight |
| 08/06/2020 | 1811.44% | BMO Capital | $112 → $108 | Maintains | Outperform |
| 08/06/2020 | 1333.58% | Wedbush | $89 → $81 | Maintains | Outperform |
| 07/13/2020 | 1669.85% | B of A Securities | $104 → $100 | Maintains | Buy |
| 06/12/2020 | 2253.9% | SVB Leerink | $129 → $133 | Maintains | Outperform |
| 05/28/2020 | 1191.99% | Morgan Stanley | $69 → $73 | Maintains | Equal-Weight |
| 05/28/2020 | 2183.11% | SVB Leerink | $125 → $129 | Maintains | Outperform |
| 05/13/2020 | 1669.85% | RBC Capital | → $100 | Initiates Coverage On | → Outperform |
| 05/12/2020 | 1882.23% | BMO Capital | $107 → $112 | Maintains | Outperform |
| 04/15/2020 | 1121.2% | Morgan Stanley | $92 → $69 | Maintains | Equal-Weight |
| 03/27/2020 | 1138.89% | Stifel | $94 → $70 | Upgrades | Hold → Buy |
| 02/26/2020 | 1528.26% | Morgan Stanley | $100 → $92 | Maintains | Equal-Weight |
| 02/19/2020 | 1563.66% | Stifel | $96 → $94 | Maintains | Hold |
| 02/03/2020 | 1669.85% | Evercore ISI Group | $86 → $100 | Upgrades | In-Line → Outperform |
| 12/13/2019 | 2289.3% | Oppenheimer | → $135 | Upgrades | Perform → Outperform |
| 12/09/2019 | 2731.76% | Wells Fargo | $242 → $160 | Maintains | Overweight |
| 11/26/2019 | 2006.12% | SVB Leerink | → $119 | Upgrades | Market Perform → Outperform |
| 11/19/2019 | 1422.07% | Evercore ISI Group | → $86 | Downgrades | Outperform → In-Line |
| 11/04/2019 | — | Wedbush | Upgrades | Neutral → Outperform | |
| 11/01/2019 | 1404.37% | Piper Sandler | $120 → $85 | Maintains | Neutral |
| 11/01/2019 | 1669.85% | Morgan Stanley | $104 → $100 | Maintains | Equal-Weight |
| 10/11/2019 | 1740.64% | Morgan Stanley | $136 → $104 | Maintains | Equal-Weight |
| 10/01/2019 | 1829.14% | Stifel | → $109 | Initiates Coverage On | → Hold |
| 08/12/2019 | — | William Blair | Downgrades | Outperform → Market Perform | |
| 08/06/2019 | 2306.99% | Morgan Stanley | $143 → $136 | Maintains | Equal-Weight |
| 06/18/2019 | 2731.76% | Maxim Group | → $160 | Upgrades | Hold → Buy |
| 06/17/2019 | 2784.85% | BMO Capital | $191 → $163 | Maintains | Outperform |
| 05/15/2019 | 2218.5% | Wedbush | $166 → $131 | Downgrades | Outperform → Neutral |
| 03/05/2019 | — | Leerink Swann | Downgrades | Outperform → Market Perform | |
| 02/26/2019 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 01/23/2019 | 2749.46% | Canaccord Genuity | $250 → $161 | Maintains | Buy |
| 12/20/2018 | — | Raymond James | Initiates Coverage On | → Strong Buy | |
| 12/19/2018 | 2112.31% | Morgan Stanley | $185 → $125 | Maintains | Equal-Weight |
| 12/06/2018 | 2023.82% | Piper Sandler | $240 → $120 | Downgrades | Overweight → Neutral |
| 11/28/2018 | 2466.28% | Leerink Swann | → $145 | Initiates Coverage On | → Outperform |
| 11/05/2018 | 3174.22% | Morgan Stanley | $186 → $185 | Maintains | Equal-Weight |
| 11/05/2018 | 2837.95% | Wedbush | $204 → $166 | Maintains | Outperform |
| 11/05/2018 | 2908.74% | Janney Montgomery Scott | $170 → $170 | Upgrades | Neutral → Buy |
| 10/15/2018 | 3191.92% | Morgan Stanley | $190 → $186 | Maintains | Equal-Weight |
| 06/19/2018 | 3970.65% | Evercore ISI Group | $175 → $230 | Upgrades | In-Line → Outperform |
| 05/31/2018 | 4147.64% | Piper Sandler | → $240 | Assumes | Overweight → Overweight |
| 05/03/2018 | 3722.87% | BMO Capital | $222 → $216 | Maintains | Outperform |
| 03/21/2018 | 3598.98% | Morgan Stanley | $152 → $209 | Maintains | Equal-Weight |
| 03/14/2018 | 3793.67% | Janney Montgomery Scott | → $220 | Initiates Coverage On | → Neutral |
| 03/05/2018 | 4183.03% | William Blair | → $242 | Initiates Coverage On | → Outperform |
| 02/26/2018 | 2590.17% | Morgan Stanley | $151 → $152 | Maintains | Equal-Weight |
| 02/22/2018 | 3758.27% | B of A Securities | $185 → $218 | Maintains | Neutral |
| 02/22/2018 | 3829.06% | BMO Capital | $215 → $222 | Maintains | Outperform |
| 01/25/2018 | — | Leerink Swann | Downgrades | Outperform → Market Perform | |
| 12/21/2017 | — | Oppenheimer | Initiates Coverage On | → Perform | |
| 12/13/2017 | — | Maxim Group | Downgrades | Buy → Hold | |
| 12/11/2017 | — | Jefferies | Upgrades | Hold → Buy | |
| 12/05/2017 | 3475.09% | Canaccord Genuity | → $202 | Initiates Coverage On | → Buy |
| 11/30/2017 | 3439.7% | Maxim Group | $170 → $200 | Maintains | Buy |
| 11/06/2017 | — | Evercore ISI Group | Downgrades | Outperform → In-Line | |
| 11/03/2017 | 2784.85% | SunTrust Robinson Humphrey | $108 → $163 | Maintains | Buy |
| 11/03/2017 | — | Morgan Stanley | Upgrades | Underweight → Equal-Weight | |
| 11/02/2017 | 2767.16% | Barclays | $151 → $162 | Maintains | Overweight |
| 11/02/2017 | — | BTIG | Upgrades | Neutral → Buy | |
| 10/30/2017 | 2767.16% | BMO Capital | $134 → $162 | Maintains | Outperform |
| 10/16/2017 | — | Evercore ISI Group | Upgrades | In-Line → Outperform | |
| 10/11/2017 | — | Jefferies | Downgrades | Buy → Hold | |
| 10/02/2017 | — | Morgan Stanley | Downgrades | Equal-Weight → Underweight | |
| 09/07/2017 | 2572.47% | Barclays | → $151 | Initiates Coverage On | → Overweight |
| 08/17/2017 | 1705.25% | Evercore ISI Group | → $102 | Initiates Coverage On | → In-Line |
| 08/07/2017 | 1758.34% | Morgan Stanley | $103 → $105 | Maintains | Equal-Weight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 08/05/2022 | -11.51% | 巴克萊 | $3 → $5 | 升級 | 重量不足的→等重 |
| 08/02/2022 | 41.59% | 雷蒙德·詹姆斯 | → $8 | 升級 | 市場表現優於→ |
| 05/24/2022 | -64.6% | 高盛 | $3 → $2 | 維護 | 賣 |
| 05/17/2022 | -46.9% | 摩根士丹利 | $5 → $3 | 維護 | 體重不足 |
| 05/10/2022 | -46.9% | 巴克萊 | $4 → $3 | 維護 | 體重不足 |
| 04/06/2022 | — | 考恩公司 | 評級下調 | 跑贏→市場表現 | |
| 04/06/2022 | 41.59% | SVB Leerink | $10 → $8 | 維護 | 市場表現 |
| 03/08/2022 | 41.59% | 富國銀行 | $12 → $8 | 維護 | 等重 |
| 03/07/2022 | -11.51% | 摩根士丹利 | $6 → $5 | 維護 | 體重不足 |
| 03/07/2022 | -29.21% | 巴克萊 | $13 → $4 | 評級下調 | 等重→減碼 |
| 03/07/2022 | 76.98% | SVB Leerink | $11 → $10 | 維護 | 市場表現 |
| 01/06/2022 | 76.98% | 摩根士丹利 | $11 → $10 | 維護 | 體重不足 |
| 11/08/2021 | 76.98% | 高盛 | $23 → $10 | 評級下調 | 中性→銷售 |
| 11/08/2021 | 130.08% | 巴克萊 | $20 → $13 | 維護 | 等重 |
| 11/08/2021 | 94.68% | 摩根士丹利 | → $11 | 評級下調 | 等重→減碼 |
| 09/22/2021 | 307.07% | 瑞穗 | $29 → $23 | 維護 | 買 |
| 08/10/2021 | 253.97% | 卡納科特·格納奇 | $86 → $20 | 評級下調 | 購買→Hold |
| 08/10/2021 | 307.07% | 高盛 | $63 → $23 | 評級下調 | 購買→中性 |
| 08/10/2021 | 342.46% | 富國銀行 | $60 → $25 | 評級下調 | 超重→等重 |
| 07/16/2021 | 519.45% | 摩根士丹利 | $36 → $35 | 維護 | 等重 |
| 07/01/2021 | 519.45% | 貝倫伯格 | → $35 | 評級下調 | 購買→Hold |
| 04/19/2021 | 537.15% | 摩根士丹利 | $45 → $36 | 維護 | 等重 |
| 03/29/2021 | 1174.29% | SVB Leerink | $69 → $72 | 維護 | 跑贏大盤 |
| 03/10/2021 | 1121.2% | 瑞穗 | $34 → $69 | 升級 | 中性→購買 |
| 03/02/2021 | 696.43% | 摩根士丹利 | $50 → $45 | 維護 | 等重 |
| 02/17/2021 | 590.24% | 摩根大通 | $76 → $39 | 評級下調 | 超重→中性 |
| 11/11/2020 | 1032.7% | 貝倫伯格 | → $64 | 開始承保 | →購買 |
| 11/11/2020 | 784.92% | 摩根士丹利 | $68 → $50 | 維護 | 等重 |
| 11/05/2020 | 873.42% | 派珀·桑德勒 | $70 → $55 | 維護 | 中性 |
| 11/05/2020 | 1333.58% | B of A證券 | $100 → $81 | 維護 | 買 |
| 11/05/2020 | 1652.15% | SVB Leerink | $133 → $99 | 維護 | 跑贏大盤 |
| 11/05/2020 | 891.12% | 蒙特利爾銀行資本 | → $56 | 評級下調 | 跑贏→市場表現 |
| 10/20/2020 | 2076.91% | 瑞穗 | → $123 | 開始承保 | →購買 |
| 08/10/2020 | 1103.5% | 摩根士丹利 | $73 → $68 | 維護 | 等重 |
| 08/06/2020 | 1811.44% | 蒙特利爾銀行資本 | $112 → $108 | 維護 | 跑贏大盤 |
| 08/06/2020 | 1333.58% | 韋德布什 | $89 → $81 | 維護 | 跑贏大盤 |
| 07/13/2020 | 1669.85% | B of A證券 | $104 → $100 | 維護 | 買 |
| 06/12/2020 | 2253.9% | SVB Leerink | $129 → $133 | 維護 | 跑贏大盤 |
| 05/28/2020 | 1191.99% | 摩根士丹利 | $69 → $73 | 維護 | 等重 |
| 05/28/2020 | 2183.11% | SVB Leerink | $125 → $129 | 維護 | 跑贏大盤 |
| 05/13/2020 | 1669.85% | 加拿大皇家銀行資本 | → $100 | 開始承保 | →跑贏大盤 |
| 05/12/2020 | 1882.23% | 蒙特利爾銀行資本 | $107 → $112 | 維護 | 跑贏大盤 |
| 04/15/2020 | 1121.2% | 摩根士丹利 | $92 → $69 | 維護 | 等重 |
| 03/27/2020 | 1138.89% | Stifel | $94 → $70 | 升級 | 持有→購買 |
| 02/26/2020 | 1528.26% | 摩根士丹利 | $100 → $92 | 維護 | 等重 |
| 02/19/2020 | 1563.66% | Stifel | $96 → $94 | 維護 | 保持 |
| 02/03/2020 | 1669.85% | Evercore ISI集團 | $86 → $100 | 升級 | 線內→表現優異 |
| 12/13/2019 | 2289.3% | 奧本海默 | → $135 | 升級 | →表現強於大盤 |
| 12/09/2019 | 2731.76% | 富國銀行 | $242 → $160 | 維護 | 超重 |
| 11/26/2019 | 2006.12% | SVB Leerink | → $119 | 升級 | 市場表現優於→ |
| 11/19/2019 | 1422.07% | Evercore ISI集團 | → $86 | 評級下調 | 勝過→同線 |
| 11/04/2019 | — | 韋德布什 | 升級 | 中性→表現優異 | |
| 11/01/2019 | 1404.37% | 派珀·桑德勒 | $120 → $85 | 維護 | 中性 |
| 11/01/2019 | 1669.85% | 摩根士丹利 | $104 → $100 | 維護 | 等重 |
| 10/11/2019 | 1740.64% | 摩根士丹利 | $136 → $104 | 維護 | 等重 |
| 10/01/2019 | 1829.14% | Stifel | → $109 | 開始承保 | →保留 |
| 08/12/2019 | — | 威廉·布萊爾 | 評級下調 | 跑贏→市場表現 | |
| 08/06/2019 | 2306.99% | 摩根士丹利 | $143 → $136 | 維護 | 等重 |
| 06/18/2019 | 2731.76% | Maxim集團 | → $160 | 升級 | 持有→購買 |
| 06/17/2019 | 2784.85% | 蒙特利爾銀行資本 | $191 → $163 | 維護 | 跑贏大盤 |
| 05/15/2019 | 2218.5% | 韋德布什 | $166 → $131 | 評級下調 | 跑贏→中性 |
| 03/05/2019 | — | 利林克·斯旺 | 評級下調 | 跑贏→市場表現 | |
| 02/26/2019 | — | 考恩公司 | 開始承保 | →跑贏大盤 | |
| 01/23/2019 | 2749.46% | 卡納科特·格納奇 | $250 → $161 | 維護 | 買 |
| 12/20/2018 | — | 雷蒙德·詹姆斯 | 開始承保 | →強勢購買 | |
| 12/19/2018 | 2112.31% | 摩根士丹利 | $185 → $125 | 維護 | 等重 |
| 12/06/2018 | 2023.82% | 派珀·桑德勒 | $240 → $120 | 評級下調 | 超重→中性 |
| 11/28/2018 | 2466.28% | 利林克·斯旺 | → $145 | 開始承保 | →跑贏大盤 |
| 11/05/2018 | 3174.22% | 摩根士丹利 | $186 → $185 | 維護 | 等重 |
| 11/05/2018 | 2837.95% | 韋德布什 | $204 → $166 | 維護 | 跑贏大盤 |
| 11/05/2018 | 2908.74% | 詹尼·蒙哥馬利·斯科特 | $170 → $170 | 升級 | 中性→購買 |
| 10/15/2018 | 3191.92% | 摩根士丹利 | $190 → $186 | 維護 | 等重 |
| 06/19/2018 | 3970.65% | Evercore ISI集團 | $175 → $230 | 升級 | 線內→表現優異 |
| 05/31/2018 | 4147.64% | 派珀·桑德勒 | → $240 | 假設 | 超重→超重 |
| 05/03/2018 | 3722.87% | 蒙特利爾銀行資本 | $222 → $216 | 維護 | 跑贏大盤 |
| 03/21/2018 | 3598.98% | 摩根士丹利 | $152 → $209 | 維護 | 等重 |
| 03/14/2018 | 3793.67% | 詹尼·蒙哥馬利·斯科特 | → $220 | 開始承保 | →中性 |
| 03/05/2018 | 4183.03% | 威廉·布萊爾 | → $242 | 開始承保 | →跑贏大盤 |
| 02/26/2018 | 2590.17% | 摩根士丹利 | $151 → $152 | 維護 | 等重 |
| 02/22/2018 | 3758.27% | B of A證券 | $185 → $218 | 維護 | 中性 |
| 02/22/2018 | 3829.06% | 蒙特利爾銀行資本 | $215 → $222 | 維護 | 跑贏大盤 |
| 01/25/2018 | — | 利林克·斯旺 | 評級下調 | 跑贏→市場表現 | |
| 12/21/2017 | — | 奧本海默 | 開始承保 | →性能 | |
| 12/13/2017 | — | Maxim集團 | 評級下調 | 購買→Hold | |
| 12/11/2017 | — | 傑富瑞 | 升級 | 持有→購買 | |
| 12/05/2017 | 3475.09% | 卡納科特·格納奇 | → $202 | 開始承保 | →購買 |
| 11/30/2017 | 3439.7% | Maxim集團 | $170 → $200 | 維護 | 買 |
| 11/06/2017 | — | Evercore ISI集團 | 評級下調 | 勝過→同線 | |
| 11/03/2017 | 2784.85% | SunTrust Robinson Humphrey | $108 → $163 | 維護 | 買 |
| 11/03/2017 | — | 摩根士丹利 | 升級 | 重量不足的→等重 | |
| 11/02/2017 | 2767.16% | 巴克萊 | $151 → $162 | 維護 | 超重 |
| 11/02/2017 | — | BTIG | 升級 | 中性→購買 | |
| 10/30/2017 | 2767.16% | 蒙特利爾銀行資本 | $134 → $162 | 維護 | 跑贏大盤 |
| 10/16/2017 | — | Evercore ISI集團 | 升級 | 線內→表現優異 | |
| 10/11/2017 | — | 傑富瑞 | 評級下調 | 購買→Hold | |
| 10/02/2017 | — | 摩根士丹利 | 評級下調 | 等重→減碼 | |
| 09/07/2017 | 2572.47% | 巴克萊 | → $151 | 開始承保 | →超重 |
| 08/17/2017 | 1705.25% | Evercore ISI集團 | → $102 | 開始承保 | →串聯 |
| 08/07/2017 | 1758.34% | 摩根士丹利 | $103 → $105 | 維護 | 等重 |
bluebird bio Questions & Answers
青鳥傳記問答
What is the target price for bluebird bio (BLUE)?
藍鳥生物(藍色)的目標價格是多少？
The latest price target for bluebird bio (NASDAQ: BLUE) was reported by Barclays on August 5, 2022. The analyst firm set a price target for $5.00 expecting BLUE to fall to within 12 months (a possible -11.51% downside). 19 analyst firms have reported ratings in the last year.
巴克萊銀行於2022年8月5日報道了藍鳥生物(納斯達克：藍色)的最新目標價。這家分析公司將目標價定為5美元，預計藍色將在12個月內跌至(可能下跌11.51%)。去年有19家分析公司公佈了評級。
What is the most recent analyst rating for bluebird bio (BLUE)?
藍鳥生物(藍色)的最新分析師評級是多少？
The latest analyst rating for bluebird bio (NASDAQ: BLUE) was provided by Barclays, and bluebird bio upgraded their equal-weight rating.
藍鳥生物(納斯達克：藍)的最新分析師評級由巴克萊提供，藍鳥生物上調了其同等權重的評級。
When is the next analyst rating going to be posted or updated for bluebird bio (BLUE)?
藍鳥生物(藍色)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of bluebird bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for bluebird bio was filed on August 5, 2022 so you should expect the next rating to be made available sometime around August 5, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閲公共財務報表，與藍鳥生物的高管和客户交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。藍鳥生物的上一次評級是在2022年8月5日提交的，所以你應該預計下一次評級將在2023年8月5日左右的某個時候提供。
Is the Analyst Rating bluebird bio (BLUE) correct?
分析師對藍鳥生物(藍色)的評級正確嗎？
While ratings are subjective and will change, the latest bluebird bio (BLUE) rating was a upgraded with a price target of $3.00 to $5.00. The current price bluebird bio (BLUE) is trading at is $5.65, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的藍鳥生物(藍色)評級被上調，目標價從3.00美元到5.00美元。藍鳥生物(Blue)目前的交易價格為5.65美元，超出了分析師的預測區間。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。